NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
STAA
STAAR Surgical Company
STAA has a slight edge over NVO overall, supported by stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STAA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
STAA's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over STAA in the historical PE scenario, which offers more potential upside but is not a forecast.
STAA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 50x | $26.78 | — |
| Cheap | 82x | $0.82 | -97% |
| Fair | 132x | $1.32 | -95% |
| Expensive | 350x | $3.50 | -87% |
| Current | 2,678x | $26.78 | — |
Historical ranges are pointers, not guarantees.
STAA's PE is in its expensive range at 2678x. If earnings grow as analysts expect, today's price would be 50x next year's earnings, in its cheap range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STAA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
STAA has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STAA on earnings, with more consistent year-over-year improvement.
STAA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.54 | +5306% |
| Q3 2026 | $0.01 | +$1.96 |
| Q2 2026 | $0.08 | +$2.01 |
| Q1 2026 | -$0.42 | +$1.02 |
| Q4 2025 | -$1.62 | -$1.21 |
| Q3 2025 | -$1.95 | -543% |
| Q2 2025 | -$1.93 | -668% |
| Q1 2025 | -$1.44 | -565% |
| Q4 2024 | -$0.41 | -195% |
STAA has returned to profit: it earned $0.01 per share over the past year, after losing money the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over STAA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STAA on profitability, with a higher operating margin.
STAA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.4M | -12% |
| Q2 2026 | $93.5M | +111% |
| Q1 2026 | $93.5M | +120% |
| Q4 2025 | $57.8M | +18% |
| Q3 2025 | $94.7M | +6.9% |
| Q2 2025 | $44.3M | -55% |
| Q1 2025 | $42.6M | -45% |
| Q4 2024 | $49M | -36% |
STAA's revenue is growing: $83M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.5% | -13 points |
| Q2 2026 | 11% | +78 points |
| Q1 2026 | 8.5% | +143 points |
| Q4 2025 | -40% | +18 points |
| Q3 2025 | 20% | +13 points |
| Q2 2025 | -68% | -80 points |
| Q1 2025 | -135% | -132 points |
| Q4 2024 | -57% | -71 points |
STAA's operating margin was 6.5% last quarter, down 13 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over STAA on cash flow, with more consistent year-over-year improvement.
STAA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26.4M | +1379% |
| Q2 2026 | $19.2M | +$48.2M |
| Q1 2026 | -$22.1M | -$14.9M |
| Q4 2025 | -$5.6M | -$508K |
| Q3 2025 | $1.8M | +$4.2M |
| Q2 2025 | -$29M | -$12.4M |
| Q1 2025 | -$7.2M | -144% |
| Q4 2024 | -$5.1M | -118% |
STAA's free cash flow has turned positive after three years mostly in the red: $18M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STAA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STAA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -52K shares |
| 1 year | +1.8% | +900K shares |
| 3 years | +4.2% | +2.1M shares |
| 5 years | +3.7% | +1.9M shares |
| Available history | +9.7% | +4.6M shares |
STAA has 51M diluted shares, up 1.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | $2M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STAA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -13.9x | Net Cash |
| Q2 2026 | -6.7x | Net Cash |
| Q3 2024 | -5.2x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
| Q1 2023 | -2.3x | Net Cash |
| Q4 2022 | -1.8x | Net Cash |
| Q3 2022 | -2.4x | Net Cash |
| Q2 2022 | -4.2x | Net Cash |
STAA has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STAA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.9 | Neutral |
| Stochastic | 69.4 | Neutral |
STAA's weekly RSI is 58 (neutral) and its Stochastic is 69 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over STAA on valuation relative to its sector.
STAA PE vs Healthcare Sector
| Metric | STAA | Sector median | Relative |
|---|---|---|---|
| PE | 2,678x | 26x | 10,260% above |
| PE % | 100 | 29 | 71 pts above |
STAA is trading at 2678x earnings, a 10260% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
STAA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.1 | 16% above |
| 20 week MA | $23.9 | 12% above |
| 50 week MA | $23.7 | 13% above |
| 100 week MA | $22.8 | 18% above |
| 200 week MA | $33.3 | 19% below |
STAA has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STAA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.5 | $81.4 | +123% |
| 2021 | $81.4 | $96.3 | +18% |
| 2022 | $96.3 | $48.4 | -50% |
| 2023 | $48.4 | $31.2 | -36% |
| 2024 | $31.2 | $24.2 | -22% |
| 2025 | $24.2 | $23.4 | -3.6% |
| 2026 YTD | $23.4 | $26.8 | +15% |
STAA has the edge over NVO on returns for 2026, with the stronger performance.